FDA approval for ovarian cancer late line treatment in the fourth quarter of 2019; Potential China NDA approval for ovarian cancer
second-line maintenance therapy; Potential China commercial launch; Completion of enrollment of China Phase 3 clinical trial for ovarian cancer first-line maintenance therapy; China
second-line ovarian cancer Phase 3 clinical trial to reach target events by the fourth quarter of 2019 with readout in the first half of 2020; Zai Lab to present data from PRIME and NORA studies at Asian Society of Gynecologic Oncology 2019; Continued enrollment of the China small cell lung cancer Phase 3 clinical trial; Initiate trials in other key indications in China.
Deciphera released updated data from a Phase 1 study of ripretinib, which continued to support the pipeline asset's potential across the broad range of KIT and PDGR-alpha mutations that occur in patients with
second-line through fourth-line gastrointestinal stromal tumors.
The two drugs -- sulfonylureas and basal insulin- are commonly prescribed to patients after they have taken metformin, a widely accepted initial Type 2 diabetes treatment, but need a
second-line medication because metformin alone didn't work or wasn't tolerated.
Few patients who are initiated on
second-line treatment for type 2 diabetes mellitus show evidence of recommended use of first-line treatment with metformin, according to research published online Sept.
M2 PHARMA-April 28, 2017-Bayer secures US FDA approval for Stivarga (regorafenib) tablets for
second-line treatment of hepatocellular carcinoma
M2 EQUITYBITES-April 28, 2017-Bayer secures US FDA approval for Stivarga (regorafenib) tablets for
second-line treatment of hepatocellular carcinoma
This is largely because patients find it very hard to keep taking
second-line drugs, which can be quite toxic, for prolonged periods of time.
The Food and Drug Administration and WHO guidelines recommend adding bedaquiline when an effective regimen (containing at least 4 effective
second-line drugs plus pyrazinamide) cannot be designed because of drug toxicity or resistance to fluoroquinolones or
second-line injectable drugs (9,10).
(4) Another potential
second-line option is the use of an alternate TKI, such as sorafenib, which showed in the INTORSECT study to have comparable efficacy to temsirolimus.
Compared with the 2012 AUA/SUFU recommendations, the 2014 guideline on "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults" adds the beta3-adrenoceptor agonist mirabegron (Myrbetriq, Astellas Pharma) as a first- or
second-line treatment option for some patients.
Inevitably, the number of patients initiating
second-line ART regimens is growing in most parts of the region, and following from this, a small but increasing number of patients are found to be failing
second-line regimens.